Exhibit 99.1

July 31, 2013

Dear Shareholders,

Your Board, management team and employees have worked hard for many years to reach that critical point when all the pieces come together. For Unilife, that time is now. A large and growing number of pharmaceutical companies are seeking to partner with Unilife in recognition of how our game-changing products, world-class team and advanced operational capabilities can enhance and differentiate their injectable therapies. Several pharmaceutical companies have selected Unilife for major drug programs that we expect will be progressively announced and generate upfront payments during this calendar year.

I expect the announcement of these programs will transform Unilife. We are advised that a commercial supply agreement for the Unifill syringe remains in the formal process of being signed by a global pharmaceutical company. Agreements with several other pharmaceutical companies have now been through multiple iterations and are fast approaching ratification. Payments are already being received from some customers for device programs prior to the finalization of pending contracts.

While I share the eagerness of many shareholders to announce these significant contracts, our top priority is to build long-term partnerships with each pharmaceutical customer and to maintain the integrity and trust of these relationships. Accordingly, we will work at the speed of each customer to finalize and announce each contract. Based upon the advanced status of negotiations with our customers, we see no reason to alter previous forecasts for up to a dozen contracts to be announced or begin generating revenue this calendar year. Indeed, the next announcement may come from any number of programs and customers. The announcement of these programs will begin to reflect the substantial and growing shareholder value being built by our continued investment in product development and expanding intellectual property portfolio.

The upfront and recurring payments generated from these contracts are likely to have a long-lasting, positive impact on our operations. Given the magnitude of some of these anticipated announcements and our confidence in their finalization, we are seeking to minimize dilution to existing shareholders as much as possible while managing our cash position to finance our growth. As previously discussed, we are working with a number of U.S. financing groups specializing in debt financing for life sciences companies like Unilife. We have received multiple financing proposals and will select the most beneficial one when appropriate. During favorable market conditions, we also have utilized our At-The-Market (ATM) facility to strengthen our balance sheet and minimize dilution as we move towards strong, accelerating revenue growth.

Having reached this important threshold in Unilife’s transformation into a commercial leader for injectable drug delivery systems, it is critical that we maintain our strength and flexibility. Accordingly, the Board and I wish to remind you that one-third of all eligible common stock is required to be voted in order to constitute a quorum for the upcoming Special Meeting of Stockholders to be held on Thursday, August 22^nd at 4:00 pm U.S. Eastern Daylight Time (Friday, August 23^rd at 6:00 am Australian Eastern Standard Time). It is important for all shareholders to exercise their right to vote. We therefore encourage you to vote prior to the August 18^th deadline, and to support the Board by voting FOR both proposals.

Thank you for your continued support.

Alan Shortall CEO

Forward-Looking Statements

This shareholder letter contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/3/2000. Amended 24/10/2005

Name of entity

UNILIFE CORPORATION

Consolidated statement of cash flows

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Reconciliation of cash

Acquisitions and disposals of business entities

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Compliance statement

Sign here:						Date: 31 July 13
		(Director)
Print name:		Alan Shortall

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Notes